Table 2. Univariate and multivariate Cox proportional hazards regression analysis of predictive classifications for progression-free survival in all 150 patients.

Characteristics	Univariate analysis				Multivariate analysis
	HR	95% CI	P		HR	95% CI	P
Gender (male vs. female)	0.727	0.455–1.162	0.18
Age (≥65 vs.<65 years)	0.776	0.535–1.127	0.18
Smoking history (yes vs. no)	0.720	0.478–1.083	0.11
Histology (squamous vs. non-squamous)	0.861	0.590–1.255	0.44
Lung metastasis (yes vs. no)	1.212	0.817–1.800	0.34
Pleural metastasis (yes vs. no)	0.794	0.548–1.152	0.23
Abdominal metastasis (yes vs. no)	1.211	0.780–1.880	0.39
Brain metastasis (yes vs. no)	0.818	0.481–1.392	0.46
Stage (IVB vs. IVA)	1.014	0.697–1.476	0.94
Treatment (IC group vs. C group)	0.458	0.306–0.686	<0.001		0.473	0.316–0.711	<0.001
Platelet (>350 vs. ≤350 ×109/L)	1.799	1.170–2.766	0.007		1.576	1.021–2.432	0.04
D-dimer (>500 vs. ≤500 ng/mL)	2.002	1.307–3.066	0.001		1.937	1.262–2.973	0.002

HR, hazard ratio; CI, confidence interval; IC, immunotherapy plus chemotherapy; C, chemotherapy.